Mon. 29 Jan 2024, 1:22am ET
Benzinga
Earnings, News
Comparable sales declined by 1%. Excluding provisions charged to sales of EUR 174 million, mainly in connection with the Respironics consent decree, the increase was 3%. This growth was driven by high-single-digit growth in the Personal Health segment and mid-single-digit growth in the Diagnosis & Treatment segment.